STOCK TITAN
  1. Home
  2. SEC Filings
  3. BETA
  4. [144] BETA Technologies, Inc. SEC Filing

BETA Technologies officer proposes $208K share sale

The remarks identify Godric's Hollow Trust U/S 12/22/20 as the source of the shares covered by the proposed sale.

Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
144

Rhea-AI Filing Summary

A Rule 144 notice for BETA Technologies, Inc. officer Kyle Clark lists a proposed sale of 10,000 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $207,706.34 and an approximate sale date of October 27, 2026. The notice also lists Kyle Clark’s earlier sales during the preceding three months.

Proposed sale 10,000 shares BETA common stock
Aggregate market value $207,706.34 Proposed sale
Shares outstanding 225,439,576 shares Common shares outstanding listed in the notice
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Original Issue Transferred to Trust financial
"Original Issue Transferred to Trust"
attorney-in-fact regulatory
"as attorney-in-fact for Kyle Clark"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BETA shares did Kyle Clark propose to sell?
The notice lists a proposed sale of 10,000 shares of BETA common stock, with an aggregate market value of $207,706.34 and an approximate sale date of October 27, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR

Keep reading

More on BETA

All BETA news

Trending in the feed

IOVA
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy Open the live feed